NICE has recommended moving Novartis’ Kisqali (ribociclib) from interim funding arrangements to regular NHS reimbursement for certain previously treated breast cancer patients. In the final ...

Kisqali is a prescription drug used with other medications to treat certain kinds of breast cancer. Kisqali can cause side effects that range from mild to serious, such as fatigue, hair loss, and ...

The web-dev ASP.NET Core framework and Xamarin.Forms' successor .NET MAUI received the lion's share of dev attention in the seventh preview of .NET 9 as Microsoft preps for a November launch at .NET ...

This type of tumor, referred in shorthand as HR+ and HER2-, accounts for roughly 70% of all breast cancer cases in the U.S. Kisqali specifically targets a protein called CDK4/6, as does Eli Lilly’s ...

Computer Vision is an exciting research area that studies how to make computers efficiently perceive, process, and understand visual data such as images and videos. The ultimate goal is for computers ...

Just a few weeks after Eli Lilly claimed a key FDA approval for its CDK4/6 inhibitor Verzenio in early-stage breast cancer, Novartis has responded with phase 3 data for Kisqali that will lead to ...

This journal utilises an Online Peer Review Service (OPRS) for submissions. By clicking "Continue" you will be taken to our partner site https://mc.manuscriptcentral ...